India, Nov. 19 -- Medivir AB (MVIR), a pharmaceutical company developing treatments for diseases with high unmet medical needs, announced that the U.S. FDA has granted Rare Pediatric Disease Designation (RPDD) to its investigational drug MIV-711 for osteogenesis imperfecta (OI), also known as brittle bone disease.
MIV-711 already holds Orphan Drug Designation in the U.S. for OI. The new designation strengthens the candidate's regulatory status ahead of a planned proof-of-concept clinical study.
Osteogenesis imperfecta is a rare inherited disorder that causes fragile bones and frequent fractures. Patients may also experience bone deformities, chronic pain and short stature. There are currently no approved treatments that address the underl...